16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.
复制标题
DOI：
10.1177/0961203320950461
复制
发表时间：
2020-10
期刊：
影响因子：
2.6
通讯作者：
Andrade D
中科院分区：
文献类型：
--
作者：
Cohen H;Cuadrado MJ;Erkan D;Duarte-Garcia A;Isenberg DA;Knight JS;Ortel TL;Rahman A;Salmon JE;Tektonidou MG;Williams DJ;Willis R;Woller SC;Andrade D
抗磷脂综合征(APS)是一种获得性自身免疫性血栓形成症，其特征是血栓形成和/或妊娠发病率与持续性抗磷脂抗体相关。第16届抗磷脂抗体国际大会APS治疗趋势工作组回顾了APS现有的和新的治疗趋势的现状，这是本工作组报告的重点。该报告介绍了APS患者的直接口服抗凝药物、抗血小板药物、辅助治疗(羟氯喹、他汀类和维生素D)、包括利妥昔单抗、belimumab和抗肿瘤坏死因子药物在内的靶向治疗、补体抑制和基于β-2-糖蛋白I的多肽的药物的治疗现状和进展。此外，报告还总结了潜在的新参与者，包括辅酶Q10、腺苷受体激动剂和腺苷增强。在每一种情况下，该报告都根据当前的技术水平为临床医生提供建议，并建议临床研究议程。启动和发展适当的临床研究需要重点设计适当的结果衡量标准，包括疾病活动性指数、最佳损害指数和特定的生活质量指数。
Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid antibodies. The 16th International Congress on Antiphospholipid Antibodies Task Force on APS Treatment Trends reviewed the current status with regard to existing and novel treatment trends for APS, which is the focus of this Task Force report. The report addresses current treatments and developments since the last report, on the use of direct oral anticoagulants in patients with APS, antiplatelet agents, adjunctive therapies (hydroxychloroquine, statins and vitamin D), targeted treatment including rituximab, belimumab, and anti-TNF agents, complement inhibition and drugs based on peptides of beta-2-glycoprotein I. In addition, the report summarises potential new players, including coenzyme Q10, adenosine receptor agonists and adenosine potentiation. In each case, the report provides recommendations for clinicians, based on the current state of the art, and suggests a clinical research agenda. The initiation and development of appropriate clinical studies requires a focus on devising suitable outcome measures, including a disease activity index, an optimal damage index, and a specific quality of life index.
登录
查看更多内容
影响因子：
16.6
作者：
Ali, Ramadan A.;Gandhi, Alex A.;Knight, Jason S.
通讯作者：
Knight, Jason S.
影响因子：
3.4
作者：
Adamson, Rosemary;Sangle, Shirish;D'Cruz, David P.
通讯作者：
D'Cruz, David P.
影响因子：
4.7
作者：
Cartin-Ceba, Rodrigo;Peikert, Tobias;Specks, Ulrich
通讯作者：
Specks, Ulrich
影响因子：
9.6
作者：
Bates, Shannon M.;Greer, Ian A.;Vandvik, Per Olav
通讯作者：
Vandvik, Per Olav
影响因子：
--
作者：
Baker, KP;Edwards, BM;Albert, VR
通讯作者：
Albert, VR